Search
tarenflurbil (Flurizan, R-flurbiprofen)
Not FDA-approved.
Indications:
- Alzheimer's disease (not effective, but then what is?) [1]
Dosage: 800 mg PO BID
Adverse effects:
- small increase in dizziness, anemia, & infections relative to placebo
- increased risk of pneumonia, Herpes zoster
Mechanism of action:
- enantiomer of flurbiprofen with clinically insignificant anti-inflammatory activity
- influences the production of amyloid via through the formation of shorter, less-toxic chains (selective Abeta42-lowering agent)
- does not slow cognitive decline or the loss of activities of daily living in patients with mild Alzheimer's disease
Interactions
drug adverse effects of NSAIDs
monitor with non steroidal anti-inflammatory agents (NSIADs)
General
pharmaceutical agents for treatment of Alzheimer's disease (Alzheimer's agent)
flurbiprofen (Ansaid, Ocufen, Ropion, Flurofen)
Database Correlations
PUBCHEM correlations
References
- Green RC et al.
Effect of tarenflurbil on cognitive decline and activities
of daily living in patients with mild Alzheimer disease:
A randomized controlled trial.
JAMA 2009 Dec 16; 302:2557.
PMID: 20009055
- Montine TJ and Larson EB.
Late-life dementias: Does this unyielding global challenge
require a broader view?
JAMA 2009 Dec 16; 302:2593.
PMID: 20009062